drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
Third-generation, irreversible, mutant-selective EGFR tyrosine kinase inhibitor (also referred to as almonertinib in some sources).
nci_thesaurus_concept_id
C133691
nci_thesaurus_preferred_term
Aumolertinib
nci_thesaurus_definition
An orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Upon administration, aumolertinib binds to and inhibits EGFR T790M, a secondarily acquired resistance mutation, inhibits the tyrosine kinase activity of EGFR T790M, prevents EGFR T790M-mediated signaling and leads to cell death in EGFR T790M-expressing tumor cells. EGFR, a receptor tyrosine kinase that is mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization.
drug_mesh_term
Aumolertinib
drug_category
SMALL MOLECULE DRUG
drug_class
Inhibitor
drug_delivery_route
Oral
drug_mechanism_of_action
Third-generation, irreversible, mutant-selective EGFR tyrosine kinase inhibitor that covalently binds the ATP site (e.g., Cys797) of mutant EGFR (including T790M), inhibits EGFR autophosphorylation and downstream MAPK and PI3K–AKT signaling, leading to growth arrest and apoptosis of EGFR-mutant tumor cells with relative sparing of wild-type EGFR.
drug_name
Aumolertinib
nct_id_drug_ref
NCT06185400